Chieh-Yu Liang
Overview
Explore the profile of Chieh-Yu Liang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
302
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Ying B, Darling T, Desai P, Liang C, Dmitriev I, Soudani N, et al.
bioRxiv
. 2023 May;
PMID: 37205450
We previously described a nasally delivered monovalent adenoviral-vectored SARS-CoV-2 vaccine (ChAd-SARS-CoV-2-S, targeting Wuhan-1 spike [S]; iNCOVACC) that is currently used in India as a primary or booster immunization. Here, we...
12.
Lin F, Doss A, Davis-Adams H, Adams L, Hanson C, VanBlargan L, et al.
Front Immunol
. 2023 Jan;
13:1033770.
PMID: 36618402
Background: Although SARS-CoV-2 vaccines have proven effective in eliciting a protective immune response in healthy individuals, their ability to induce a durable immune response in immunocompromised individuals remains poorly understood....
13.
Scheaffer S, Lee D, Whitener B, Ying B, Wu K, Liang C, et al.
Nat Med
. 2022 Oct;
29(1):247-257.
PMID: 36265510
The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants in the Omicron lineage has resulted in diminished Coronavirus Disease 2019 (COVID-19) vaccine efficacy and persistent transmission. In this...
14.
Zimmerman O, Doss A, Kaplonek P, Liang C, VanBlargan L, Chen R, et al.
Cell Rep Med
. 2022 Jun;
3(6):100653.
PMID: 35688161
Individuals with primary antibody deficiency (PAD) syndromes have poor humoral immune responses requiring immunoglobulin replacement therapy. We followed individuals with PAD after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination...
15.
Darling T, Ying B, Whitener B, VanBlargan L, Bricker T, Liang C, et al.
Med
. 2022 May;
3(5):309-324.e6.
PMID: 35584653
Background: Since the emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2019, viral variants with greater transmissibility or immune-evasion properties have arisen, which could jeopardize recently deployed vaccine-...
16.
Boosting with variant-matched or historical mRNA vaccines protects against Omicron infection in mice
Ying B, Scheaffer S, Whitener B, Liang C, Dmytrenko O, Mackin S, et al.
Cell
. 2022 Apr;
185(9):1572-1587.e11.
PMID: 35452622
The large number of spike substitutions in Omicron lineage variants (BA.1, BA.1.1., and BA.2) could jeopardize the efficacy of SARS-CoV-2 vaccines. We evaluated in mice the protective efficacy of the...
17.
Ying B, Scheaffer S, Whitener B, Liang C, Dmytrenko O, Mackin S, et al.
bioRxiv
. 2022 Feb;
PMID: 35169795
The B.1.1.529 Omicron variant jeopardizes vaccines designed with early pandemic spike antigens. Here, we evaluated in mice the protective activity of the Moderna mRNA-1273 vaccine against B.1.1.529 before or after...
18.
Ying B, Whitener B, VanBlargan L, Hassan A, Shrihari S, Liang C, et al.
Sci Transl Med
. 2021 Nov;
14(630):eabm3302.
PMID: 34846168
Although mRNA vaccines encoding the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) prevent COVID-19, the emergence of new viral variants jeopardizes their efficacy. Here, we assessed the...
19.
Ying B, Whitener B, VanBlargan L, Hassan A, Shrihari S, Liang C, et al.
bioRxiv
. 2021 Aug;
PMID: 34462745
Although mRNA vaccines prevent COVID-19, variants jeopardize their efficacy as immunity wanes. Here, we assessed the immunogenicity and protective activity of historical (mRNA-1273, designed for Wuhan-1 spike) or modified (mRNA-1273.351,...
20.
Han J, Ganti K, Sali V, Twigg C, Zhang Y, Manivasagam S, et al.
PLoS Pathog
. 2021 May;
17(5):e1009517.
PMID: 33970958
It is well documented that influenza A viruses selectively package 8 distinct viral ribonucleoprotein complexes (vRNPs) into each virion; however, the role of host factors in genome assembly is not...